Response to botulinum toxin may predict response to peroral pyloromyotomy in patients with gastroparesis.


Journal

Endoscopy
ISSN: 1438-8812
Titre abrégé: Endoscopy
Pays: Germany
ID NLM: 0215166

Informations de publication

Date de publication:
06 2023
Historique:
medline: 29 5 2023
pubmed: 24 11 2022
entrez: 23 11 2022
Statut: ppublish

Résumé

BACKGROUND : Patients with gastroparesis who have undergone prior intrapyloric botulinum toxin injection (BTI) may seek an opinion regarding peroral pyloromyotomy (POP). There are only two small reports assessing the role of BTI as a predictor for successful treatment with POP. We performed a retrospective cohort study to assess whether symptomatic improvement after BTI predicts a response to POP. We included 119 patients who had undergone both BTI and POP at Cleveland Clinic Ohio or Cleveland Clinic Florida from January 2016 to September 2019. 65.5 % of patients had symptomatic improvement after BTI. Gastroparesis Cardinal Symptom Index (GCSI) scores were available for 74 patients, with 64 % achieving a response to POP, defined as a decrease in mean GCSI ≥ 1. In multivariable analysis, response to BTI (odds ratio [OR] 7.7 [95 %CI 2.2-26.1]) and higher pre-POP GCSI score (OR 2.3 [95 %CI 1.2-4.6]) were independent predictors of response to POP. Clinical improvement after BTI is a predictor of response to POP in patients with gastroparesis. This information may aid in improving patient selection for POP.

Identifiants

pubmed: 36417930
doi: 10.1055/a-1986-4292
doi:

Substances chimiques

Botulinum Toxins EC 3.4.24.69

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

508-514

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

Dr. Tolga Erim has a teaching contract with Boston Scientific although has not received any royalties from it.

Auteurs

Vaibhav Wadhwa (V)

Center for Interventional Gastroenterology, University of Texas Health Science, Houston, Texas, United States.

Adalberto Gonzalez (A)

Department of Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, Florida, United States.

Francisco Azar (F)

Department of Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, Florida, United States.

Harjinder Singh (H)

Department of Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, Florida, United States.

Kapil Gupta (K)

Department of Gastroenterology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States.

Hong Liang (H)

Department of Clinical Research, Cleveland Clinic Florida, Weston, Florida, United States.

Alison Schneider (A)

Department of Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, Florida, United States.

Jeffery Ponsky (J)

Department of General Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, United States.

Tolga Erim (T)

Department of Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, Florida, United States.

John Rodriguez (J)

Department of General Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, United States.

Fernando J Castro (FJ)

Department of Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, Florida, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH